Other resources Drug information Monoclonals Glivec News Velcade Thalidomide Contact form Print this page Bookmark this page Send to friend Glivec (Imatinib mesylate) Click here to find out more about recent reports of heart complications as a side effect of Glivec. "Gleevec (STI571) is the first of a new class of antiproliferative agents called signal transduction inhibitors, which interfere with the pathways that signal the growth of tumor cells. Gleevec (STI571) is targeted to the specific biochemical abnormality found predominantly in a form of leukemia called chronic myeloid leukemia (CML)." Manufacturer's web site - not objective information! Free full text papers on Glivec The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review Garside, R., Round, A., Dalziel, K., Stein, K., and Royle, P. Health Technol.Assess. 6 2002 1-162, The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations Marin, D., Marktel, S., Bua, M., Armstrong, L., Goldman, J. M., Apperley, J. F., and Olavarria, E. Haematologica 87 2002 979-88, Multifaceted approach to the treatment of bcr-abl-positive leukemias O'Dwyer, M. Oncologist 7 Suppl 1 2002 30-8, More free full text papers on Glivec STI571: targeting BCR-ABL as therapy for CML Mauro, M. J. and Druker, B. J. Oncologist 6 2001 233-8, Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia Druker, B. J. and Lydon, N. B. J Clin Invest 105 2000 3-7, Imatinib mesylate Baker, D. E. Rev.Gastroenterol.Disord. 2 2002 75-86,

privacy | disclaimer Registered charity 216032 (England & Wales) SC037529 (Scotland) Limited Company 738089 © Leukaemia & Lymphoma Research 2010    We subscribe to the HONcode principles of the Health On The Net Foundation.